Clinical Trials Logo

Nephroblastoma clinical trials

View clinical trials related to Nephroblastoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05985161 Recruiting - Solid Tumor Clinical Trials

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether selinexor is an effective treatment for people under the age of 51 who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.

NCT ID: NCT05245123 Recruiting - Neuroblastoma Clinical Trials

Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families

PsyRareCare
Start date: February 21, 2022
Phase:
Study type: Observational

Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings. The aim of the present research project is to examine the psychosocial burden of the children with rare solid abdominal tumors and their family in order to draw attention to a possible psychosocial care gap in this population.

NCT ID: NCT04423484 Recruiting - Nephroblastoma Clinical Trials

Therapeutic Recommendations for Nephroblastoma

GFANEPHRO20
Start date: July 1, 2020
Phase:
Study type: Observational

The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.

NCT ID: NCT04168788 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL

MVO
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Hepatic veno-occlusive diseases (VOD) during cancer treatment in children are serious toxicities that have occurred with interruptions of chemotherapy and risk of relapse. In addition, these toxicities have a negative impact on the patient's quality of life, serious long-term sequelae and are potentially fatal in children. The risk factors associated with the occurrence of these complications are, to date, unknown, at the exception to the exposition to certain treatments (6-thioguanine, busulfan, actinomycin D, radiotherapy, etc.). To understand the effects of this toxicity and those of susceptibility to the disease becomes a major issue in the treatment of these children.

NCT ID: NCT00001509 Completed - Neuroblastoma Clinical Trials

A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor

Start date: July 1996
Phase: Phase 2
Study type: Interventional

A body of preclinical data has provided a strong rationale for evaluating the combination of IFN-alpha with retinoic acid. The two drugs have different mechanisms of action and, when used in combination, show enhanced activity in both adult and pediatric tumor cell lines. The combination of the antiproliferative and differentiation inducing effect of retinoids together with the antiproliferative, immunostimulatory and differentiation-potentiating effects of IFN-alpha warrant clinical investigation of this combination for the treatment of refractory pediatric malignancies.